Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

May 7, 2020

NASDAQ US Health Care Pharmaceuticals earnings 94 min

Earnings Call Speaker Segments

Jennifer Ruddock

executive
#1

Thanks, Crystal. Hello, everyone, and thanks for being with us this afternoon. Joining us today are our President and CEO, Howard Robin; our COO and CFO, Gil Labrucherie; Dr. Jonathan Zalevsky, who leads R&D; and Dr. Wei Lin, who heads Development. During this call, we anticipate making forward-looking statements about our business, including results from clinical trials, the timing and plans for upcoming clinical trials, the timing and plans for upcoming presentations of clinical data, the therapeutic potential of our drug candidates, outcomes and plans relating to health authority regulatory actions and decisions, estimates and predictions concerning how the COVID-19 pandemic will affect our business and clinical trials, financial guidance, and certain other statements about our business's future. Since these statements concern the future, they carry inherent uncertainties and risks that are hard to predict, and many of them lie outside our control. Significant risks and uncertainties appear in the Form 10-K we filed on February 28, 2020, which you can find at sec.gov; we assume no obligation to update any of these statements, whether because of new information, future developments, or otherwise. A webcast of this call will be accessible as a replay on the IR page of Nektar's website at nektar.com. Before I turn things over to Howard, I want to mention a small housekeeping matter. Because of the shelter-in-place restrictions in San Francisco, all of us are dialing in from separate locations; so to help the call flow smoothly, I'll moderate the Q&A portion for our team so that we can steer clear of technical problems during that portion. Thanks so much, and we appreciate your patience while we work to make sure there are no technology disruptions for those listening. Having said that, I'll pass the call to our President and CEO, Howard Robin. Howard?

Howard Robin

executive
#2

Thank you, Jennifer, and I appreciate everyone joining us on this call today. First, I'd like to address something I'm sure is on all your minds: our response to the challenging circumstances brought about by the COVID-19 pandemic during the past few months. This virus has significantly impacted the health and well-being of our communities, and like each of you, we're striving to make the necessary adjustments to our operations while continuing to lead and manage the company effectively. The situation is constantly evolving, and we'll continue to adapt our approach. That said, I want to highlight a few key points. As we start collaborating to navigate today's conditions, our focus rests on three key objectives. The first is safeguarding our workforce's well-being while keeping critical on-site work going so that research and development—including lab work and manufacturing—can move forward. The second is making sure every one of our trial investigators, along with their teams, is able to keep delivering excellent care and uninterrupted study treatment access to cancer patients. And the third is making sure our clinical trials face as little disruption as possible, and that the data gathered from these studies keeps its integrity and quality. Let me start with our top priority. For staff who are still coming in to handle clinical and other essential work at our sites — that includes manufacturing and lab operations — we've put extra safety measures in place, such as more protective gear and keeping people physically apart. For those whose jobs can be done well off-site, Nektar has brought in work-from-home arrangements, and we're giving them the tech resources they need so their work continues without disruption; on this front, we've been following every local, state, county and federal rule. Right now, we don't expect any manufacturing supply disruptions, and that covers the work already in progress to scale up commercial supply of bempeg. For bempeg, NKTR-262, NKTR-255, and NKTR-358 — the trials either already running or scheduled to begin during 2020 — we hold enough clinical trial material to treat every patient enrolled. Along with our manufacturing partners, we keep evaluating the situation on a routine basis. On top of that, our research group keeps pushing forward to produce our next IND candidate, which would let us reach the company's next IND filing in early 2021. Turning to the second priority: more than 200 investigator sites worldwide take part in our oncology clinical studies. We've been in close contact with the investigators at each site, as well as our partners at the CRO, to evaluate how each site is doing and whether they have enough staff, and to give them resources and assistance. The situation keeps shifting. Even so, Nektar has adopted an approach that lets sites keep bringing in new patients and lets new investigator sites get started. That approach has worked well up to now, and Wei will go into more detail about these efforts shortly. Our third priority, which matters just as much, is making sure our clinical trials are conducted properly and with integrity. What that means is that if any protocol deviations come up during this period, we capture them thoroughly, gather any patient data that might be tied to a COVID diagnosis, and stand ready to monitor for any disruption to key treatment or scan visits caused by COVID travel restrictions. Guidance on how to conduct clinical trials has been put out by the FDA, and we anticipate that guidance will keep changing; given that, our most critical tasks right now are to keep a close watch on our study sites so that patients satisfy the proper eligibility criteria required by the protocol and so that data get gathered and followed correctly too. A number of you have asked about the ways COVID could impact the schedules for our clinical trials. We're able to offer some initial observations, but we should note that because this situation keeps shifting, there's a great deal of uncertainty. As a result, we'll need to continue assessing those schedules throughout the year, and we're getting a clearer picture of both the timing and the extent of COVID's effects. During this time, the clinical development and operations groups at Nektar remain intensely focused on managing the five immuno-oncology studies that Nektar sponsors. Let me list them for you: the bempeg plus nivo trial in first-line bladder cancer, the bempeg plus nivo trial in first-line renal cell carcinoma, the PROPEL trial combining bempeg with pembro, the REVEAL trial of NKTR-262 alongside bempeg, and the NKTR-255 trials. To begin with, I want to speak to a few inquiries we've received — we've gotten only a small number of reports involving patients in our trials who have either a suspected or confirmed COVID diagnosis. Out of the five clinical trials I just named, as of today, we've received merely four reports of patients who were diagnosed with COVID, and that's across more than 200 investigator sites. Now, on the subject of new trials getting underway, Nektar is still on track to begin the adjuvant melanoma trial in the third quarter. Based on our current evaluation, and provided nothing negative related to COVID emerges externally during the year's second half, we view that as very much within reach. Our adjuvant melanoma trial's protocol is nearly finalized, and right now we're focused on locating and bringing aboard investigator sites, which would let us launch before this year ends. Turning to the first-line bladder cancer trial, the rate of enrollment hasn't been affected up to this point, and we expect to reach our target for enrollment during the summer. That puts us on course to reach the study's primary endpoint time line at some point in mid-2021; and to remind everyone, the study's primary endpoint is ORR by independent review among patients whose CPS score is under 10. For the first-line renal cell carcinoma study, we remain on track with the enrollment projections we had before COVID, which means we're likewise on track to reach the first interim analysis on the primary endpoint of overall survival during the first quarter of 2022. Enrollment continues in our PROPEL trial, which looks at bempeg combined with pembro in non-small cell lung cancer and got underway late in 2019. The launch of PROPEL got delayed at European investigator sites because of COVID. That said, in countries where the virus has hit less hard, we're still bringing a number of those sites online. Our approach remains cautious: we move ahead only when a site has demonstrated the ability to manage clinical trial oversight and services, along with patient care, to the necessary standard. As we've mentioned previously, for this trial we had expected to have initial safety data and preliminary ORR results from 10 to 20 patients dosed across the dose escalation and non-small cell lung cancer cohorts by November. What we now anticipate is receiving that either at the end of this year or during the first quarter of 2021. Work on our Phase I/II REVEAL trial is still moving forward. We recently expanded that study, which means it now evaluates the recommended Phase II dose of NKTR-262 across up to 24 patients who have relapsed and refractory melanoma. That was the first instance where we evaluated both investigational agents administered simultaneously. While escalating the dose, we observed substantial TLR activation inside the tumor microenvironment, and we were able to establish the safety profile for NKTR-262.

Howard Robin

executive
#3

Later this year, we intend to submit these dose escalation findings, either for possible presentation at a medical meeting or for publication as a manuscript. Turning to NKTR-255, which is our IL-15 agonist program and also our most recent clinical candidate, we are actively enrolling patients in the first-in-human clinical study of NKTR-255, which started late last year. We are continuing to initiate sites in this study, and we still aim to finish the dose escalation portion by the end of this year. Naturally, whether we meet that goal depends on the number of dose cohorts we must enroll before reaching a maximum tolerable dose. In the initial group of participants who joined the trial, we already possess strong biomarker proof that the IL-15 pathway is being engaged by the drug, and we intend to share this information either later in 2020 or during the early part of 2021. Just to remind everyone, this trial is testing NKTR-255 initially by itself, and afterward together with daratumumab and rituximab for multiple myeloma and non-Hodgkin's lymphoma, respectively. Now I'd like to discuss the trials our collaborators are conducting. Many of you have likely picked up on recent conference calls held by major drugmakers in which they described varying strategies for handling clinical studies that are underway or in the planning stages throughout the COVID pandemic. A lot of businesses expect that by the latter half of 2020, standard procedures for clinical trials will be back in place across most nations. Typically, that's involved pushing study schedules back by roughly three to six months. Every one of our collaborators has taken a different approach; as for BMS, our partner, while the COVID crisis continues, they've said openly that they've stopped opening any new investigator sites for every clinical study they're running throughout the entire company. At the moment, BMS is conducting two active bempeg trials: the first-line melanoma trial and the muscle-invasive bladder cancer trial. As you're aware, BMS handles the operational side and the scheduling for those trials. BMS is still enrolling participants in these trials at investigator locations where in-person monitoring of new patients is permitted. Right now, given that COVID remains an ongoing issue and BMS hasn't revised any study timelines, Nektar anticipates an effect on recruitment for both trials, potentially resulting in three-to-six-month delays. We're currently collaborating closely with BMS to figure out when they'll lift or adjust any enrollment-limiting restrictions. And just to remind everyone, under the amended BMS agreement, we got the $25 million milestone payment during Q1 of this year tied to kicking off the muscle-invasive bladder cancer trial for bempeg plus nivo. Additionally, BMS intends to launch the TKI combination renal cell carcinoma trial, along with a Phase II trial examining bempeg combined with nivo in first-line non-small cell lung cancer, later this year. Turning to Lilly, the partner we work with on NKTR-358, our Treg stimulatory program: due to the COVID situation, enrollment has been temporarily halted for the Phase I multiple dose trials in psoriasis and atopic dermatitis. Even so, Lilly continues watching the circumstances and assessing how investigator sites are performing, so they can determine the best time to resume enrollment in these studies. Our expectation remains that Lilly will launch two Phase II trials during this year — one involving lupus patients and another in a different autoimmune disease state — with both expected to begin in the latter portion of 2020. We understand that Lilly's team is looking at every possibility for getting these trials underway, such as concentrating on opening investigator sites in nations where COVID's current impact is low or minimal. We therefore value their commitment to finding inventive routes to move these new trials forward. Overall, we're pretty pleased that Lilly has stayed committed to NKTR-358 and put together such broad development plans for it — those plans really show what this new mechanism could do when it comes to treating autoimmune disease. Before I hand things over to Wei, I'd like to flag several additional data presentations on our calendar for this year. First off, on the melanoma cohort within PIVOT-02: as I think most of you know, last year the FDA granted Breakthrough Therapy Designation for the combination of bempeg and nivo in patients with metastatic melanoma, and that decision rested on encouraging results, among them a strong complete response rate seen in our PIVOT-02 study. During our SITC presentation last November, we discussed results from that group, which had about 18 months of median follow-up. At that time, blinded independent central review showed a complete response in 34% of patients, target lesion shrinkage of 100% in 42%, and reductions greater than 75% in 47% — close to half. When December 2019 ended, we had completed another blinded assessment of the PIVOT-02 melanoma cohort, giving us a data cutoff with three additional months of follow-up beyond what we presented at SITC. I'm very pleased to report that with a median follow-up now at 21 months, median PFS remains unreached for patients in this group. We likewise keep observing responses deepen in these patients, and we intend to share updated findings from an even later data cut at SITC 2020; also concerning bempeg, results from the dose escalation portion of PIVOT-02 will appear in a publication in a cancer journal during May. Lastly, we are preparing to submit for publication further manuscripts covering the bladder and kidney cancer patient cohorts from PIVOT-02; as for NKTR-358, we recently finished the Phase Ib multiple ascending dose trial in lupus patients that Nektar ran as part of our collaboration with Lilly. Initial results from the Phase Ib study have been cleared for showcasing at the upcoming online EULAR gathering. In addition, we intend to share further findings from that identical trial later this year at the 2020 American College of Rheumatology Meeting, known as ACR. With that said, I'll pass the floor to Wei, who will provide a more detailed overview of several approaches we are implementing across Nektar's ongoing clinical trials, aimed at addressing the COVID situation and ensuring both the soundness and completion of these investigations during this challenging time. Wei?

Wei Lin

executive
#4

Thanks, Howard. I want to take a moment to walk through the thorough approach we've put together so that we're addressing both of the priorities Howard brought up earlier. First, making sure patients can keep getting their study treatments in our clinical trials without interruption. Second, making sure the way our clinical trials are run, and their integrity, stay intact. For patients who are right now enrolled in the trials Nektar is conducting, we're doing everything we can so that those in heavily impacted regions, and in places where restrictions are severe, can keep receiving their study treatment along with suitable care and monitoring. When circumstances permit and within the rules that apply, we're bringing in additional patient concierge services that offer transportation choices and resources to people in their studies. We're also letting patients go to nearby facilities for their scheduled study treatment and scan visits instead of traveling greater distances whenever that's feasible. And we're putting a lot of emphasis on using every possible approach to give our investigator sites the right resources they need to keep up care and monitoring of patients, which includes virtual monitoring and telemedicine, so that both patient and site staff safety are protected. We've stepped up our work to monitor what's happening at sites. We've stayed in ongoing contact with site investigators and staff. We're concentrating on giving site staff information about proper data entry and about the options available to patients. We're also verifying that site staff are reachable and capable of following any new measures that get implemented. Our clinical monitors are concentrating on gathering all pertinent data regarding any protocol deviations, data entry, or any study conduct that we might need to hand over to the FDA later on. As Howard said, the FDA has put out guidance on how clinical trials should be conducted, and we keep watching that guidance. We're also working alongside others in our industry to give feedback to the FDA on different clinical trial conduct problems that come up because of the COVID-19 pandemic. We're letting sites keep enrolling new patients, and we keep starting up new study sites. That said, we're very focused on whether the patients being enrolled are appropriately eligible and on making sure every enrollment criterion is satisfied. On top of that, we want to confirm that a site has the right staffing and isn't too heavily affected by COVID-19 before we add a new site to any of our clinical studies. I'm glad to say that so far, we've observed outstanding patient compliance in our clinical studies, especially when it comes to getting study treatment and scheduled scans, with just a single patient across all the studies Nektar runs having missed a scan, and nobody having missed a study treatment. We've been incredibly impressed by how deeply engaged our investigators and their staff have been, and by the remarkable care they're giving their patients through this challenging period. We think that thanks to the steps we're taking, we can steer through the present circumstances properly, which lets us keep moving our clinical programs ahead. Before turning things over to JZ, who will walk us through what we're doing with NKTR-358 and NKTR-255, I'd like to speak to the questions that keep coming our way regarding the switch of the interim response rate endpoint in our first-line melanoma trial. As everyone is aware, bempeg plus nivo earned a Breakthrough Therapy Designation in this setting, and that came on the strength of the high complete response rate seen in the first-line melanoma population. The Phase III trial BMS is running has three endpoints: overall response rate, or ORR; progression-free survival, or PFS; and overall survival, or OS. The initial endpoint is an interim analysis in which a very small amount of alpha gets spent to compare ORR in the double combination of bempeg plus nivo against ORR in the nivolumab monotherapy arm; what we're seeking is six-month duration of follow-up for a specific number of patients enrolled in the study. Given how high our complete response rate has been, a lot of you have asked if the interim could instead be changed to examine complete response rate within each arm. Our partner, BMS, and we are evaluating that possibility, and we're hoping for an update on the matter prior to the year's end. Until then, the trial keeps its three original endpoints: ORR, PFS and OS. The study's original design, which drew on CheckMate 067, modeled the PFS endpoint at approximately six to seven months after overall response rate; keep in mind, though, that this was merely a projection, and since it is event-driven and tied to enrollment rate, that timing may shift. For ORR as well as PFS, blinded independent radiology review will handle the analysis of results. That process, then, will also influence when any data analyses can be completed. Once we draw nearer to reaching these endpoints, we ought to be able to fine-tune our time line. Remember that ORR serves as an accelerated approval endpoint. Only a small amount of alpha was spent on it, and PFS is what will support a full approval; with that said, I'll pass the call to JZ to talk more about our NKTR-358 and NKTR-255 programs.

Jonathan Zalevsky

executive
#5

Thank you, Wei. There are a couple of programs I want to walk through in a bit more detail: first, NKTR-358 and what we're planning for the lupus study, and second, our IL-15 program, NKTR-255. Starting with NKTR-358, as Howard mentioned, we're going to share the initial results from the Phase Ib multiple ascending dose trial, which enrolled patients with mild-to-moderate lupus, at this year's European League Against Rheumatism, or EULAR Meeting, in early June. Because the conference is virtual, we'll also hold a virtual webcast on the morning of June 5 to go through the data with investors and analysts. A number of autoimmune conditions, systemic lupus among them, are tied to lower regulatory T-cell counts, diminished Treg function and/or less IL-2 being produced. These Treg deficiencies play a significant role in how these autoimmune diseases develop; with NKTR-358, we're aiming to correct the Treg abnormalities seen in disease and to create an IL-2 molecule capable of selectively stimulating Tregs far more effectively than native IL-2 can. You'll remember that at last year's EULAR Congress, we shared findings from our first-in-human single dose trial, which demonstrated that NKTR-358 was safe, well tolerated and displayed a dose-proportional PK profile, with prolonged exposure and a half-life of roughly eight to nine days. Importantly, NKTR-358 produced a marked and selective dose-dependent expansion of CD25(bright) Tregs; by contrast, no measurable changes were seen in the numbers or percentages of CD4 and CD8 conventional T cells at any dose tested. In the study we'll present at this year's EULAR Congress, we assessed multiple ascending dose regimens of NKTR-358 in lupus patients, both to study the safety, tolerability and pharmacodynamics of NKTR-358 and to help inform the design of the Phase II study of NKTR-358. As Howard said, that Phase II study in lupus patients is slated to begin in the second half of this year, and we're excited about how this program is advancing. Turning to NKTR-255. The dose escalation portion of this Phase I/II study is moving forward. The trial is assessing the safety, pharmacokinetics and pharmacodynamics of NKTR-255 as a monotherapy, and then will expand into combination with antibodies that act through an ADCC mechanism, including daratumumab and rituximab. We intend to enroll as many as 40 patients with relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma in the dose escalation part of the study. We've also built a robust biomarker program into this trial, which includes measuring the NKTR-255 effect on multiple immune cell populations, especially the expansion of NK cell numbers along with their activation and function. Our goal is to provide a thorough assessment of the NKTR-255 mechanism of action. As a reminder, unlike other IL-15 approaches, NKTR-255 was designed to capture the full biology of the IL-15 pathway, which specifically means NKTR-255 is designed to capture all the receptor-ligand interaction available through targeting the IL-15 agonist pathway. That means NKTR-255 can work as a major multiplier of natural killer cells, and it can also help memory CD8 T cells survive and multiply. Like Howard said, we aim to wrap up the monotherapy dose escalation part of the Phase I study before this year ends, and the early biomarker findings from the first patients dosed have us enthusiastic; with that, I'll hand things over to Gil so he can walk through the financials.

Gil Labrucherie

executive
#6

Thank you, JZ, and good afternoon to all of you. During this call, I'll go over our 2020 financial guidance, and that guidance has not changed. To begin, our financial position is exceptionally strong — we closed out the first quarter holding $1.5 billion in cash and investments. As we mentioned during the earnings call we held last time, our intention is to pay off the $250 million of senior notes still outstanding during the second quarter of this year; that repayment was in fact finished in April, so it will show up in our Q2 2020 balance sheet. Paying off the senior notes has made our balance sheet stronger and will produce roughly $20 million in yearly interest savings going forward. Once we factor in the senior note repayment along with the cash we expect to use this year, we continue to expect to finish 2020 with no less than $1 billion in cash and investments. As discussed during our prior earnings call, and in line with our guidance, we took a $45.2 million impairment charge during the first quarter, which wraps up our NKTR-181 activities. Our loss per share for the first quarter came to $0.78, and that figure includes the $0.25 loss per share tied to this impairment charge. Now I'll move on to our 2020 financial guidance, which stays the same. Before going further, I want to point out that we aren't revising our full year financial forecast because of COVID-19 impacts, since progress on our clinical pipeline is largely staying on track, as Howard explained earlier in this call. For 2020, our full year GAAP revenue guidance is still $140 million to $145 million; that figure includes $50 million in milestone payments from BMS plus $90 million to $95 million from royalties, product sales and other revenue. As Howard noted, we recognized and received the first $25 million milestone tied to BMS' launch of the muscle-invasive bladder cancer study, which happened in January of this year. The second $25 million milestone relates to the launch of the adjuvant melanoma study and is still scheduled for Q3 of this year. As a reminder, the remaining $90 million to $95 million of GAAP revenue is still anticipated to be recognized on a fairly ratable basis across the four quarters of this year. Our GAAP R&D expense guidance hasn't changed either. We expect 2020 GAAP R&D expense to fall between $475 million and $500 million, which includes roughly $70 million of noncash depreciation and stock compensation expense. Our G&A expense for 2020 is still expected to land between $105 million and $115 million, which includes approximately $45 million of noncash depreciation and stock compensation expense; and as I went through earlier, we still expect to close the year with at least $1 billion in cash and investments after finishing the repayment of our $250 million in senior debt this quarter. With that, I'll open the call to questions. Operator?

Peter Lawson

analyst
#7

Hello, and thank you for allowing me to ask my questions. I suppose my first one concerns JZ, specifically around 255. Could you discuss the timing for when we might get a look at the first patient data? Also, what specific findings would you need to observe to advance that program?

Howard Robin

executive
#8

Of course. I appreciate it, Peter. My apologies, Jennifer. Right, thank you, Peter. So, regarding NKTR-255, as we mentioned previously on this call, we are now in the process of initiating the dose escalation. From the initial handful of individuals dosed in our trial, we have observed some highly compelling target engagement information. The types of outcomes we are hoping to observe are, clearly, an evaluation of the comprehensive safety profile, how well it is tolerated, its pharmacokinetics, and its pharmacodynamics—essentially all the standard elements found in any initial trial in humans, as you move a drug into the clinic for the very first time and carry out a dose escalation. However, for 255 in particular, we had gained a great deal of knowledge from our prior lab work. If you recall, we tested this molecule in non-human primates, in mice, and in other species. We observed how it impacted immunological parameters. For instance, we noted increases in natural killer cells and their continued presence. We also detected shifts in the activation status of these cells, and we even shared information—presented findings—regarding the broader differentiation within the natural killer cell population. Peter, this represents the sort of biology that can only be attained through an IL-15 pathway. Consequently, as we transition into the clinic, our goal is to replicate all these types of results. The clinical study itself incorporates a comprehensive biomarker component, which enables us to track these sorts of alterations. It permits us to evaluate the natural killer cells and the CD8 T cells, examining them across various compartments, including blood and tissue. Thus, we are quite eager to share the findings we are gathering in this trial. We believe it is plausible that either later in this year or at the start of the next one is when we will be able to do so. This is contingent on the dose escalation proceeding as intended, and the sorts of things we hope to derive from that escalation are, as I outlined, a mix of safety, tolerability, the PK, and the biomarkers within the program.

Jennifer Ruddock

executive
#9

Peter, thanks — this is Jennifer speaking. I'll hand that over to Wei if he can take it. But first, on your question: I realize that with the interim readout in first-line melanoma, comparing the two arms is tough right now. Do we have any sense of when that might come? And how has the conversation shifted, or have you talked more with the FDA on that point?

Wei Lin

executive
#10

Absolutely, and thank you, Jennifer, for raising that. We're actively collaborating with our partner BMS as we engage with the health authority. Once the health working discussion wraps up, we will certainly share our feedback. This process definitely involves not just the FDA — the EU health authorities are, I believe, also planned to be part of it, since obtaining macro authorization should be global, and therefore securing input globally from all health authorities, all the major ones, is really critical for us to implement the change. The existing design featuring a three end point has already been reviewed and endorsed by the relevant health authorities. So prior to making any change, it's not only FDA engagement but also health engagement that we must secure before moving forward with the change, and once that's complete, we'll be sharing that information.

Peter Lawson

analyst
#11

All right, thanks a lot. I'll get back in line again.

Howard Robin

executive
#12

Of course.

Tyler Van Buren

analyst
#13

Hi there. Hope everyone's having a good afternoon, and I appreciate you taking my questions. So, for my first one, it's about the melanoma PIVOT-02 update that came with the December cutoff. My understanding is you mentioned median PFS hadn't been reached at 21 months, and when I go back to SITC, that was 18.6 months of follow-up. At that time, you said median PFS couldn't be worse than 15 months. So would it be reasonable to apply that same kind of three-month difference here, which would suggest median PFS can't be worse than 18 months, or I'd love to hear what you think?

Jennifer Ruddock

executive
#14

Wei, could you take that one? Thanks.

Wei Lin

executive
#15

Alright, thank you Jennifer, and I appreciate the question. So, the relationship isn't necessarily a straight line, and certainly when follow-up goes on for a longer period, the minimum PFS would be prolonged as well. However, since what we showed reflects an interim assessment while we conduct regular reviews of the data, and we weren't prepared to make that public at that point, I wouldn't — we haven't yet run an analysis that would genuinely allow us to estimate what that minimum PFS figure would be right now. It is certainly longer than what we saw at SITC, and we intend during the back half of this year to provide an update on the melanoma data. When that happens, we'll be able to give specifics on what this translates to regarding PFS as our follow-up work continues.

Tyler Van Buren

analyst
#16

All right. And following up on that, could you say, I suppose, what the median PFS is — at which point in terms of median PFS, how many months would you folks feel truly certain that a meaningful difference is showing up here with the combo, since if you look at other Phase II trials. A few clients have noted that they demonstrated 20 months median PFS. And after that in Phase III, they showed no effects. Even these time points look impressive compared with nivo monotherapy at seven months for nivo, being at 11.5.

Jennifer Ruddock

executive
#17

Wei, I'd like you to respond to that too.

Wei Lin

executive
#18

Alright, so I think I'll split this into two pieces to properly tackle it. One piece is the median, and the other piece is the hazard ratio. Ultimately, when the FDA and other health care reviewers look at the data for a full approval that's based on PFS, it truly comes down to those two numbers together. So the median is definitely quite important, but the hazard ratio provides the full separation of the two curves across the whole span of the curve; so those two things matter a great deal as well. So it's a — it has always been — it's always hard to claim that a specific median is enough, because what really counts is the overall shape of the curve. At times the median can bubble, at times the median may not concave somewhat, but if the remaining portion of the curve adds up to a very strong hazard ratio difference, that is also extremely, extremely meaningful as well. All right, so the current evidence, in my view, clearly suggests a pretty substantial gap between the NIVO BEMPEG group and the NIVO group, even if that comes from PIVOT-02; then when it comes to translatability — that's the second thing — what I truly want to get into is whether the Phase two results from PIVOT-02 can carry over to a registrational Phase three, and that really addresses the core of what you're asking, which is: of course, there's a long history of Phase two findings not holding up in Phase three, so how confident are you, really, that they will? And because of that, you can look back and find plenty of cases throughout history, and I really want to stress this point — most of the time, when something can't be translated, it's because the endpoint you're looking at in Phase two has no real link to the endpoint you're looking at in Phase three. So for instance, with a lot of diseases, Phase two is actually designed around a PFS endpoint. Then when you get to Phase three, it's designed around an OS endpoint. And for some diseases, those two endpoints really don't line up well at all. In CRC, for example, they do line up quite well. But with many other tumor types, they really don't line up well at all. However, when you don't have a solid endpoint to rely on, folks tend to lean on whatever else is available, which frequently means progression-free survival, with the expectation that it will carry over into overall survival. That gap in the linkage is exactly what has driven a number of the disappointments we've seen historically. In our own situation, though, with first-line metastatic melanoma, our added assurance came from work the FDA did and shared at ASCO back in 2019. That FDA analysis, which a lot of you already know about, drew on data covering nearly 5,000 patients from all the registration trials that had been filed seeking approval in first-line metastatic melanoma, and it performed a very comprehensive meta-analysis. What they wanted to know was how tightly response rate actually ties to progression-free survival and overall survival — and specifically, how well depth of response correlates, not using the arbitrary RECIST 1.1 threshold of a 30% shrinkage in tumor size, but rather across every cut point. They examined 25% tumor shrinkage, 50% tumor shrinkage, 75% tumor shrinkage, and additionally full disappearance of all target lesions. For each one of those subgroups, they checked: what's the PFS, what's the OS? And is there a robust correlation across all these cut points? What they found is an extremely strong trend, not just with targeted agents such as BRAF and MEK inhibitors, but particularly with immunotherapies like nivolumab, pembrolizumab, and ipilimumab. What they found was that how deeply a patient responds tracks very closely with how long they live, and that holds for both PFS and overall survival. The clearest signal showed up specifically among patients who got past a 75% reduction, and even more so in those whose disease vanished entirely. That's essentially the foundation — the biggest gap between what we observed in PIVOT-02 and what ultimately ties back to survival comes down to our CR rate. Per the FDA's analysis, when a patient's target lesions disappear completely, the one-year PFS, and the one-year PFS — and OS — that figure is certainly high. Yeah, so the FDA conducted a thorough meta-analysis, and that gives us a very clear picture: what you see in terms of depth of response does carry over, or at least connects strongly, to the PFS and OS those registration trials ultimately showed. That's exactly why, when we look at our CR rate, we believe there's a good chance it will convert into some form of survival benefit — and potentially a substantial one. I hope that addresses what you were asking.

Tyler Van Buren

analyst
#19

That's very helpful. Thank you.

Howard Robin

executive
#20

Okay. Sure.

Chris Shibutani

analyst
#21

Thank you so much. This one might be directed at JZ. In PROPEL, of course, the combination effort you're running includes a chance to test various bempeg doses—especially, as I recall, the higher ones. That's something you started talking about more than 6 months back. What I'd like to know is whether, at this point, you've seen or learned anything that's prompting you to think about taking bempeg into further development activities—whether for the indications you already have or for new ones—in some different manner.

Howard Robin

executive
#22

Thanks, Chris. In fact, I'll have Wei address that. He has been handling the dose escalation portion of PROPEL. After that, I'll turn it over to JZ for his thoughts. Thanks, Wei.

Wei Lin

executive
#23

Yeah. Of course. Without a doubt. So maybe the PROPEL study can help me take a step back and consider the larger picture. The PROPEL study actually consists of two components: a dose optimization portion, and then there is a focused extension, essentially a Phase 2 trial nested within it, examining specifically non-small cell lung cancer in the first-line setting. So our reasoning for conducting a dose optimization, despite the molecule already being in the registration phase, is really twofold. First, we've gained an enormous amount of knowledge about this molecule as we've advanced. It remains a molecule in the clinical development stage. And although we have complete confidence in the six-microgram per kilogram dose combined with nivolumab across all our ongoing registration studies — and that's underscored by the fact that the data is strong enough to secure an FDA breakthrough designation, which is essentially the highest recognition of the potential benefit this combination could deliver to patients — and together with our BMS colleagues, we've launched a number of registration studies, all founded on data we produced in PROPEL. So we strongly believe that six-microgram per kilogram is a highly active dose and we have comparative data to support that. And certainly, that's also reinforced by the confidence and investment from our BMS colleagues as well as the breakthrough designation from the FDA. That said, we've learned an enormous amount from dosing many patients and managing the AE profile, and we believe we can actually enhance how we manage adverse events in patients and possibly even increase the dose further. And as you're aware, different diseases have differing sensitivity to immunotherapy. In lung cancer, relative to, let's say, melanoma, the level of sensitivity is actually somewhat — it isn't as pronounced. So, for example, nivo as a single agent or pembro as a single agent is active across all expression subgroups in melanoma, but that isn't the case in lung; so the existing approval is really only for PD-L1 positive, not for the all-comers population, and the predominant use of pembrolizumab is in the 50% and above population. Given that, we felt it would be very useful to really increase the dose somewhat, see whether we can, with a new management guideline in place, find an even higher dose and generate even stronger benefit for patients in a disease that's more challenging than melanoma when it comes to how responsive it is to new therapy. So that's the dose determination and the rationale behind why we're indicating that. Simultaneously, we're conducting the expansion in first-line non-small cell lung cancer. And then combining with pembrolizumab, the mono — in a combination because pempro currently is the established first-line standard of care in the first-line study, so.

Chris Shibutani

analyst
#24

So is there any willingness at all on that, or does it seem promising?

Howard Robin

executive
#25

So the study is still running, we've dosed a handful of patients, and as Howard mentioned, we intend to share a portion of that data at an upcoming conference, either late this year or early next year.

Chris Shibutani

analyst
#26

All right. You're really on your best behavior. I realize you won't reveal anything. Perhaps I could pose something regarding partnerships. So, looking back over time, you folks established an excellent connection with Bristol. That had been arranged around a sort of timeline goal, and as I recall, 1 year ago, you extended things into September. After that came the renegotiated contract, and I believe it was announced as extended into September, essentially during the pre-COVID period, and now we're in a COVID setting where everybody wants to purchase time. I'm just wondering about that renegotiated contract. Does it include some kind of scope clause permitting them to maneuver within the next 3 or 6 months? Is there a timeline we ought to keep in mind, since you have a way out? I'm just interested, because clinical trials are progressing and completion schedules are clearly all constrained right now, and I'm curious specifically about the Bristol renegotiation, or possibly some of the other more significant partnerships you've had with the folks at Pfizer or Gilead?

Gil Labrucherie

executive
#27

Thank you, Chris. Howard, could you respond to that, Howard?

Howard Robin

executive
#28

Okay, Chris, hello. Well, I mean, clearly the contract contains no provision allowing either party to walk away because of a force majeure event like this. But here's the thing — each organization handles the job of keeping trials going during a situation like this in its own way. Nektar has actually done pretty well when it comes to bringing sites on board and getting patients enrolled. Some level of delay is inevitable, though. On the whole, though, we're advancing while dealing with certain holdups. Take other firms, like BMS — they paused activity right across their entire portfolio. No additional sites will be brought on board by them. At least not until they have a clearer picture regarding the COVID-19 situation. That's why we mentioned a possible delay of three to six months. Nothing in the agreement truly shifts because of that, as far as I can tell, and we continue to collaborate very closely with BMS in pushing these programs ahead. The programs we're conducting within the collaboration are progressing well. Soon enough, I'm confident, they'll work out how to reopen site enrollment and how to bring patients in remotely, just as every other organization is doing. So yes, a delay may occur. In all likelihood, some of those studies will face a delay, but I don't view it as something carrying any contractual consequence. That holds as long as our relationship with them remains strong, and it is. The teams have shifted and developed over time. Working alongside BMS, I believe, all is proceeding without friction aside from COVID-19. Delays are simply always going to happen. Every clinical study comes with its own set of difficulties, yet I believe everyone is convinced that bempeg and nivo in first line melanoma, in metastatic melanoma, deliver a substantial benefit; and when you examine the PFS data we've generated thus far in the PIVOT-02 study, we're — I can't imagine a figure below 21 months. In my view, 21, 21.5 months would represent the floor for median PFS; so, having said that, when you set that beside nivo by itself, which comes in at six and a half months, I'd call that pretty striking. And bear in mind, as Wei mentioned before — and this is the part everyone, I believe, finds thrilling. What Wei noted before is that I don't believe you can necessarily line this up against other difficulties that firms have encountered in going from Phase two to Phase three. First, our endpoints remain the same. Second, no toxicity appeared in Phase two that would force us to reduce the dose as we enter Phase three, something other firms have been compelled to do. So, I'd say it's as apples-to-apples as it gets. And I believe BMS should be, and indeed is, as enthusiastic about it as we are; but no, nothing in the contract covers this sort of circumstance. Nobody ever could have imagined it. So from my standpoint, both companies are conducting themselves well together, and I'd like to see everything advance in a respectable manner.

Chris Shibutani

analyst
#29

Great. And finally, whenever your staff is on Zoom calls with the people from Gilead, do they plead to get one of your products into a COVID therapeutics study, which might give the stock a nice retail bump?

Howard Robin

executive
#30

Well, here's what I can tell you. We have definitely reviewed all the literature, and a great deal of it indicates that patients whose lymphocyte counts are low don't fare particularly well with COVID-19. And if you're able to raise their lymphocyte levels, those patients with lymphocyte levels actually do much better with COVID-19. So, this is something we're examining. This is something we're discussing. And we haven't made any plans as of yet, but if we decide to, if we arrive at an approach to move forward, we will certainly share it with everyone.

Howard Robin

executive
#31

Chris Shibutani asked: thanks, and thanks once more for the opportunity to ask. Then an analyst who didn't give a name said: hello, I'm Yuko, sitting in for Jessica on this call, and we appreciate you fielding our questions. You're about to begin a 180 patient Phase 1/2 dose optimization and expansion trial in non-small cell lung cancer that BMI will be conducting. Could you give us a summary of that trial, covering which doses are going to be assessed during the dose optimization portion? Also, will patients be chosen according to PD-L1 status, or based on some other biomarkers? Howard Robin replied: thank you, Yuko. I'm going to hand it over so Wei can describe how the BMS study is structured for, and then move on to small cell lung cancer? Thanks, Wei.

Wei Lin

executive
#32

Yeah, thank you. That trial’s design is also quite close to PROPEL’s. It isn’t complete at this point, though, so there’s a limit to how much I can get into right now. At a broad level, it would resemble PROPEL in that we’d increase the dosage past 6 micrograms; also, we would bring in individuals spanning OPR expression so we can genuinely see whether combining bempeg with nivolumab extends the activity checkpoint into the low-pressure group and the negative group too; therefore, results from that trial plus the PROPEL trial would let us and our partners evaluate what an ideal and strongest Phase III trial design should be.

Analyst

analyst
#33

Great. Thank you.

Difei Yang

analyst
#34

Good afternoon. And thanks for taking my question, just a quick one on NKTR-255; so you have a couple of trials ongoing in liquid tumor. How do you think about the opportunity will follow and where do you see the biggest opportunities for IL-15.

Howard Robin

executive
#35

Thank you, Difei. I'm going to ask JZ to answer that, JZ.

Jonathan Zalevsky

executive
#36

Sure, absolutely — there are quite a few compelling possibilities when it comes to solid tumors. If you think about pairing our approach with targeted antibodies, we understand that part of how those antibodies work involves effector function. In tissue, what do we usually observe? Lower numbers of natural killer cells, correct? That means we depend on antibodies that operate via direct signaling — EGFR-binding antibodies, for instance. At the same time, we're hoping those antibodies can also trigger oncology-related mechanisms through their effector function within the tissue. One of our big-picture hypotheses regarding 255 is that beyond all those mechanisms, we can also push natural killer cells into the tumor itself. I believe you've seen some of the data we shared at other conferences showing that even in a mouse model with a fully intact immune system, or in a xenograft that still had NK cell confidence — even when tumors were implanted into peripheral tissue, such as the flank, the pie — administering 255 still allowed you to drive NK cells into those peripheral tumors. You're well aware of this, right? That isn't a lymphoid type of tumor — it's not a liquid tumor in any way. This is a standard solid tumor that NK cells are capable of populating. We showed that whether you combine with Herceptin, HER-2 types of bindings such as Herceptin and HER-2 and others — across a variety of tumor models, whether xenographic, fully competent, or even in the PIVOT case — you can activate those kinds of activities in the solid tumor space. So as we look at clinical opportunities, some things that really interest us are combinations, for instance, with agents such as cetuximab. We already recognize there are possibilities in targeting the NK cell compartment alongside cetuximab. We've observed other antibody combinations accomplish that too. So I think that represents one very distinctive opportunity. And naturally, there's truly a whole wealth of additional opportunities, since you can rapidly go past cetuximab to other solid tumor targeting antibodies and think about further lines of therapy. I hope that addresses your question, Difei.

Difei Yang

analyst
#37

Yes. That's quite useful. Just a single brief follow-up from me regarding bempeg. At the time you send out reminders, what does the MTD look like for bempeg? Concerning the trial, it seems as though you intend to increase the dose up to 10 micrograms per kilo, so what would the MTD be?

Jennifer Ruddock

executive
#38

Wei, do you want to handle that one?

Wei Lin

executive
#39

Okay, yes. So with the design we have right now, we can keep escalating the dose until we reach 12 micrograms per kilogram, and that's double what we're using in the registration studies currently. Now, clearly, in the end, the MTD is one factor that feeds into the decisions about RPTD, but beyond that, we'll be reviewing the full picture of the data, covering both safety and efficacy, and on the safety side, as patients receive treatment for a longer period, whether tolerability stays well behaved.

Difei Yang

analyst
#40

Thanks, Wei, and appreciate you fielding this.

Wei Lin

executive
#41

Of course.

Bert Hazlett

analyst
#42

Yes, of course. I appreciate you fielding this. Apologies if somebody already raised it, but regarding the PIVOT-02 melanoma cohort, could it be that you have already reached the floor of 21 months when it comes to PFS for that group? Any news on the PIVOT-02 melanoma cohort, specifically PFS, would be wonderful.

Jennifer Ruddock

executive
#43

JZ, would you like to handle that one?

Jonathan Zalevsky

executive
#44

Absolutely, Bert — good to talk with you. And you're right, I do want to make that clear: your read on it is accurate. Based on how the data look right now, we have at least 21 months of PFS duration. That's really encouraging, isn't it? We keep following this cohort as it evolves and keep monitoring the patients. Of course, this reflects the sort of staying power we already shared last year. That durability is continuing to stretch out. And the PFS is extending even further. We're eager to provide another update on this cohort. We'd aim to do so, maybe, at a medical meeting later in the year.

Bert Hazlett

analyst
#45

All right. Thanks; we're eager for that too.

George Farmer

analyst
#46

Hello, good afternoon. I appreciate you taking my question. I want to go a bit deeper on PIVOT-02 and the melanoma cohort. From what I remember at SITC, although the median for PFS hadn't been reached yet at 18 months, the 12-month PFS appeared to be roughly 53%; that suggests that if perhaps 1 or 2 patients had disease progression, the curve might shift down into the lower half of the graph. Can we safely state that nobody has progressed from that point onward? Also, are you actually tracking every patient? Or have certain patients dropped out of follow-up and simply get censored at different time points? Any thoughts on any of that would be terrific.

Jennifer Ruddock

executive
#47

Wei, would you like to begin, or JZ, either one of you?

Wei Lin

executive
#48

JZ, if you want to start first? Yes. I'll add in.

Jonathan Zalevsky

executive
#49

Yes, certainly. So, George, those are excellent inquiries. What we'd like to do is provide a data update at a medical conference toward the end of 2024. At that point, we can walk through every detail of the data, since beyond the topics you raised regarding durability — correct — we can also address how responses deepen, plus the other types of overall impact that patients have experienced. I also need to keep in mind that these are patients who by now have been receiving treatment for quite an extended period, correct? So, as you observed the last time we provided an update, we saw patients who reach maximal benefit, sustaining extremely profound responses or complete response in numerous instances across more than 12 months of further treatment. Therefore, we would supply that level of detail within that sort of evaluation. And we can even go through the spider classes, as we do — you know, one-on-one, as we would at the upcoming event where we can truly reveal the data later in 2024.

George Farmer

analyst
#50

Do you expect that you will also be sharing the overall survival data?

Wei Lin

executive
#51

I think say that...

Howard Robin

executive
#52

Wei, do want to —

Wei Lin

executive
#53

Yes.

Howard Robin

executive
#54

Sure. All right, Wei, you have the floor.

Wei Lin

executive
#55

Yeah. So I'd say that at this point, the survival data we have stretches pretty far out. Because of that, our main objective has really been to characterize the PFS. That's the study's primary endpoint, and it's what will serve as the foundation for securing full approval. So that struck us as the more meaningful thing to do. As things stand now, with the shape that curve is taking, pinning down the OS would be genuinely difficult.

George Farmer

analyst
#56

All right. Then, JZ, about 358 and how the lupus data gets presented — the Phase Ib lupus data. You've got presentations lined up at 2 conferences, EULAR and ACR? If there's any difference at all, what's going to set those 2 presentations apart?

Jonathan Zalevsky

executive
#57

Yeah, so, George, I'd say. That's a good question. One factor is that since EULAR will happen as a virtual conference. It's clear to us that achieving that same level of visibility is tougher. The program, since ordinarily you're accustomed to that big conference with everyone attending and the chance to socialize the results; our expectation is that ACR, when it arrives for Rheumatology, happening in November, probably won't be a virtual conference. I mean, setting COVID to one side, we're projecting a different situation roughly 6 months out. And so there, we'd be aiming for the actual, we'd be aiming for the actual in-person conference setting. Something we did a year ago when the single ascending dose data was presented is that we split the clinical data into 2 parts. So as an example, at EULAR during the SAD study, we went over the safety and pharmacokinetics, plus the Treg pharmacodynamics demonstrating the dose-dependent expansion that we showed. Keep in mind, we demonstrated roughly a 17 fold rise in Treg levels compared to baseline at the highest dose we tested in that study; and afterward at ACR, we dive far deeper into the phenotype of patients who received NKTR-358. So in that setting we examined cytokine responses very carefully; we examined the Tregs and their activation status very carefully. And we also performed, as you remember, the methylation studies of the, the methylation studies of the promoter, again truly going deeper into the immunology; so that's a factor you can weigh for how we'll split the data with EULAR and ACR in mind. And then, naturally, the central point of the multiple ascending dose study is that it involves lupus patients. So we're assessing 358 in the disease immune system. And naturally, we're assessing multiple doses of the drug, rather than just a single dose; so EULAR is truly just around the corner. It's hardly a month off. So you'll get the early look at the data and afterward a far larger showcase of it coming at ACR later in the year.

George Farmer

analyst
#58

All right. And last, might 358 be able to address the cytokine storm tied to COVID?

Jonathan Zalevsky

executive
#59

That's quite an intriguing thing to ask. 358, without a doubt, does bring about regulatory T cells. And indeed, since you know our data, it's capable of triggering that polyclonal regulatory T cell reaction. So as an idea it's quite fascinating, with some subtlety involved. Something we understand regarding COVID and the cytokine storm is that those cytokines appear to come from non-lymphoid sources, correct? Usually they're innate types of cytokines, such as IL-6, plus others connected to CRP, for instance. Thus our general view is that lymphoid cells are able to counteract that. So it's a really intriguing notion, a really intriguing concept. Yet at present, everything we're planning around 358 stays very much planted in the autoimmune disease area.

Howard Robin

executive
#60

Alright, fantastic. Many thanks. Apologies — my line was muted. I appreciate you taking my question. Perhaps I could ask something that builds on what was discussed regarding your IL-15 agonist 255. You've already shared a bit about what you hope to observe in the data set from the initial Phase one readout. Given that other IL-15 candidates with differing approaches have recently been entering the clinic, I'm wondering whether you could go into more detail about the way your IL-15 was designed by your team. And what sorts of differentiators should we be watching for in that early data set that you expect to have around year end? Thank you. Thanks, Arlinda. JZ is going to handle that one, JZ.

Jonathan Zalevsky

executive
#61

Okay, Arlinda. As you're aware, one objective we had with our 255 program involved wanting to preserve every receptor ligand interaction that's possible — all of the ones IL-15 relies upon when it signals naturally, the way that cytokine behaves in the human body like a naked cytokine. We also recognize that it possesses a minimum of two — actually, no fewer than three distinct binding modes. It's able to signal via the dimeric beta gamma receptor complex, wherever such a complex is present on any cell, on any cell type. Beyond that, signaling can also occur through a trimeric receptor complex, in which an IL-15 receptor alpha specific subunit forms a complex with beta gamma; that signaling mode differs from the IL-2 pathway, since here the IL-15 alpha receptor subunit may be expressed on the very same cell as beta gamma — what we refer to as signaling. Alternatively, it can be expressed on an adjacent cell, handing off to a beta gamma on a nearby cell; that process is a kind of cell contact mediated signaling, which we term trans presentation. Those, then, represent all three modes of natural IL-15 dependent biology. The immune system employs all three. As a result, we aimed to make sure that the biology of 255 could mirror the complete spectrum of biological activity that naturally occurring IL-15 provides. So fundamentally, our strategy is quite distinct from a lot of the rival programs out there, because almost every one of those approaches relies on the IL-15 cytokine being manufactured as a therapeutic agent bound to the extracellular portion of the IL-15 receptor alpha. There are different versions of that concept. A few of them utilize the whole receptor. Others incorporate just a sushi domain. And as you're aware, some depend on an FC fusion to build a two-armed complex consisting of the cytokine plus the receptor. But despite these differences, every one of them is built on that identical foundational collection of design concepts. We've also got a few distinctive properties that set this apart. At SITC last year, we gave a presentation where we shared research that directly compared, side by side, the assemblies with the cytokine bound to the receptor against native IL-15 or NKTR-255. A number of notable distinctions came through. For instance, receptor internalization patterns varied among the designs relative to native 255. We also saw cellular distinctions in Granzyme B generation within NK cells. And when looking at an attack PBMC culture, we picked up differences involving CD14 monocytes capable of intracellular expression. We noticed similar patterns when looking at Granzyme B induction. With either the native IL-15 or the 255 molecule, those responses weren't really well supported or triggered by the assemblies containing both the receptor and the cytokine complex. That's one distinction, in our view. By using a 255 design like this, we ought to see a very meaningful shift in how the immune system can be engaged via the IL-15 pathway, and that seems to translate into results like reduced tachyphylaxis when dosing is repeated, plus a range of other potential benefits.

Aydin Huseynov

analyst
#62

Hello, and thanks for fielding my questions — I also want to say I appreciate every safety step that's been put in place around the site. I have a few things to ask regarding the bempeg melanoma trial, plus one follow-up on the guidance. Starting with melanoma: could you confirm where the Phase three melanoma study stands, and how many patients have been enrolled up to now? Also, since PFS appears to be anticipated in the first quarter of 2021, might we be able to learn the complete response figures sooner than that — perhaps near the end of this year, or possibly at the very start of next year?

Jennifer Ruddock

executive
#63

Thank you, Aydin. Wei, could I have you take that one?

Wei Lin

executive
#64

Absolutely, and I appreciate the question. Let me clarify one thing first: our guidance does not indicate that PFS will land at the start of the year. What we've said is that, from a response rate perspective, that initial endpoint would likely be reached possibly during Q1 of next year. Also, based on how the study is designed — the design as it stands now — our original projection was that PFS might arrive six to seven months following the OR endpoint. As we've mentioned previously, we are currently talking with health authorities about a possible switch to the first endpoint, moving it from OR to CRR. Beyond that, given such a change plus the enrollment that's already underway, the gap between the CR readout and the PFS readout, should we make that change, might not match the six to seven months. Part of the reason is that PFS is genuinely an event-driven readout. So I'd like to be clear regarding the guidance we've given so far. As for your first question — how many patients are able to enroll — that really comes down to study conduct. With a study that's ongoing, we generally don't share those figures. When enrollment is fully complete, information about the completion of enrollment will be provided. Thank you.

Aydin Huseynov

analyst
#65

All right, thanks for that. I just want to make sure — so at the start of 2021, we should expect to see the CR number alongside the RR number, correct?

Howard Robin

executive
#66

Yes, that's what we're guiding to right now.

Aydin Huseynov

analyst
#67

All right, thank you for that. I have one more thing about the financial guidance. What I'm trying to figure out is this: since some trials are being delayed, either until later in the year or, in a few cases, moved into the following year, I want to get a handle on cash burn. Why does it remain unchanged from what you previously told us, when there could be lower costs tied to R&D as well as overhead?

Howard Robin

executive
#68

Yeah, I appreciate you asking. As was mentioned during the call, and as Howard walked through, a lot of the studies we've got underway — especially those conducted internally — are still progressing as planned. Naturally, that means our expense guidance wouldn't be affected, and whatever other adjustments might come up are fairly small in scope. So we don't — based on where things stand right now, my sense is there will be some effect on our R&D costs. Certain ones depend on activity levels, others don't. That leaves us at ease with the guidance we've given. No revisions are being made right now.

Jennifer Ruddock

executive
#69

Alright, thanks a lot. I appreciate that. Hello, and thanks for letting me ask some questions. My first one is about RCC. It feels like the target keeps shifting given all these combos, and the CheckMate 9ER data now appear quite strong for nivo plus cabo. So I wanted to know whether those findings alter how you see the chance for bempeg plus nivo in RCC? Then I have a follow-up about 358, if there's time. That sounds good, Jay. Thanks. Wei, I'll have you take the RCC question and talk about the landscape.

Wei Lin

executive
#70

Alright, yes. So I'd say without a doubt, the RCC space keeps changing. At present, there's a nivo plus AP pairing, and also checkpoint plus TKI, with both of those involving pembro and avelumab, and just recently a new nivo as well. So our thinking comes down to two points, really. First, pairing bempeg with nivolumab gives patients one more option for treatment. The TKI, though, can be applied across several settings. It may be given alongside a checkpoint in the first-line setting, or it might be given afterward as a monotherapy treatment. So I believe — so depending — if you speak with various physicians globally, they're truly capitalizing on these choices and applying them in different ways. There remain some physicians who'd rather give the IIL combo in the first-line setting, while others prefer a TKI combo and then save that TKI option for the first-line setting. I think what we're aiming for here is to bring in one more treatment option. Now, we anticipate a safety profile that differs from what a checkpoint plus a TKI combination provides, and beyond that it hinges on the efficacy we can achieve. I believe it does provide a distinct treatment option and likewise gives physicians a chance to keep a TKI for a later line of therapy instead of using it all up in the first line. So that's the first point. And secondly, as has been shared before, PMS is running a Phase I trial with a triple combination of bempeg plus nivo and then TKI, and that trial is anticipated to begin. And so that kind of combination begins once the patient progresses onto a study, onto a study, and can provide further treatment options involving that line of therapy.

Jay Olson

analyst
#71

Excellent; that really helps with that thorough assessment. Then I suppose, regarding 358, it appears a handful of novel lupus therapies have won approval across the last 50 years. I believe been leased to could be among just a few. However — and at present several encouraging candidates are being developed, such as the new molecules from Astrazeneca and Biogen. I was curious about your view on how the lupus field will change and how the 358 mechanism stacks up against anifrolumab and 559.

Howard Robin

executive
#72

Nice one, JZ.

Jonathan Zalevsky

executive
#73

Alright, I'll take that one. Yes, yes, glad to address it. So yes, you've really nailed the diagnosis and description of the issue extremely well. So apart from Rituxan, which arrived a number of years back, there genuinely have been no approvals; and honestly, there had never really been any sort of truly compelling trial results until anifrolumab in the bacon showed up; and what we observed there involved some fairly exciting data in Phase II, and afterward we observed Phase III data. The Phase III data for an a came across as a bit more puzzling, correct, as you're aware. Another thing we're seeing there is that the endpoints used in lupus trials might be moving again. We saw that happen first when Benlysta got approved, and we could see the same thing happen with any. But here's one big point to keep in mind: when you look at all the mechanisms that have been tried as treatment targets, they overlap a huge amount, right? They go after the same kinds of pathways, they zero in on the same specific slice of immunology. And we keep running tons of studies on mechanisms that are incredibly, incredibly alike. A key reason Tregs are so compelling as a possible therapy for lupus is that these patients are known to show a distinct defect within their Treg compartment. We're aware that when lupus patients move toward moderate to severe disease, their IL-2 levels are low. Even when normal stimuli that would trigger expression are present, and even with normal low amounts of IL-2, the response is diminished. They also show decreased regulatory T cells. There's an imbalance involving TH17 and Treg cells, with Th17 becoming overly dominant while Treg counts fall. Reports also indicate that suppressive capacity of Tregs is reduced in people with lupus. Lupus is a heterogeneous disease made up of many components, and we have to accept that. Regulatory T cells represent a quite distinctive biological characteristic that appears tied to the malfunction seen in patients who come in with this illness. And at this point we've seen a number of clinical trials in which IL-2 at low dosage was given to treat lupus. And in these — several studies, for example, one conducted in China and another in Germany — we've seen rises in Tregs caused by low-dose IL-2. Beyond that, we've noticed some effectiveness that came out of those trials; so this is essentially the use of a first-in-class kind of mechanism for treating lupus. So I'd say that amounts to one rather thrilling possibility. There's another thrilling prospect for us, which is, naturally, we've demonstrated already that NKTR-358 is capable of inducing Tregs — in terms of quantity, in terms of how long the expansion lasts, and even regarding the enhancement of their suppressive function — in a manner that IL-2 simply cannot achieve. No low dose IL-2 regimen of any type can generate the mass quantity, that enormous level of Treg inductions, that we can achieve with 358. So taken together, we believe all of this constitutes a quite sound and compelling scientific rationale for moving forward into lupus, and that is the reason this is going to be the initial Phase two study we will be launching with Lilly; and as Howard mentioned, it won't be blocked. You'll observe further Phase two studies across other indications following lupus. And per our contract, the two companies have agreed to conduct as many as four Phase II studies. So we anticipate the complete expansion of that during this year and into the next one.

Jay Olson

analyst
#74

That's really useful. Thanks a lot for taking the questions. Karen Jenkins: This is Karen Jenkins <<inaudible>> on behalf of Paul. I was curious whether you might say a bit about your capacity to move NKTR-350 forward beyond a few of the Lilly trials, and whether you have looked into possible indications, where you might go after them either through other partnerships or by yourselves?

Jennifer Ruddock

executive
#75

JZ, that one's yours to answer.

Jonathan Zalevsky

executive
#76

Right, and regarding NKTR-358, we basically entered into something like a licensing-style collaboration alongside Eli Lilly. So our work with them on NKTR-358 is exclusive. As I said, the 358 program has a fairly broad scope, correct? You could picture taking the Treg mechanism and applying it across a variety of autoimmune diseases, and that is exactly what the two of us are doing jointly. But this is truly a program for which Lilly is our exclusive partner, and every bit of its development happens in direct collaboration with Eli Lilly.

Analyst

analyst
#77

All right, thanks. And after that, I believe you mentioned that in the PROPEL update you still have between 10 and 20 patients, though that has been delayed by a couple of months. Beyond this postponement, is there any effect we should anticipate when it comes to patient enrollment — might we perhaps see the bottom of that range because of COVID-19 or something similar?

Jennifer Ruddock

executive
#78

Wei, you can take that one.

Wei Lin

executive
#79

Alright, yes. So the plan is for this trial to roll out on a worldwide basis — across the U.S., the EU, and Australia. Given the sites we've chosen, we anticipate that most patients will be enrolled from Europe. Because of how the pandemic has hit Europe, there's been a hold-up in getting sites up and running. We're actively reviewing sites across Europe. There's a great deal of variation, as you pointed out, in how severely different countries have been impacted. What's occurred in Italy and Spain differs substantially from what's occurred in, for instance, Germany. So we're proceeding in a very deliberate way, seeking to grasp the impact both at the level of individual sites and at the country level, and aiming to be highly opportunistic about how we bring sites online and enroll patients. As we said earlier during this call, what matters most to us is ensuring the correct patients are placed onto the study and that we don't sacrifice eligibility standards because of the continuing pandemic. Beyond that, we would only bring a site online and enroll patients there if that site has shown it has the complete capability to carry out the protocol — to genuinely look after the patients and to perform all the treatments along with the tumor assessment. It's under those conditions that we intend to keep pushing forward with the study. So I'd say that since we're only a couple of months into the pandemic, precisely forecasting the impact over the next six months would be genuinely tough right now. Even so, our team is working diligently to meet those criteria and to ensure the study moves ahead as we had already hoped.

Analyst

analyst
#80

Yes, thank you.

Daina Graybosch

analyst
#81

Thanks a lot for taking these. Two things from me, and feel free to handle them in whichever sequence works. First, regarding the PROPEL or BMS trial that your team intends to run in first line non-small cell lung cancer — could that potentially be structured as a small randomized study, the way an increasing number of companies are doing with I-O combination? Also, at what point would that call get made? Second, on 358: other firms have their own IL-2 or Tregs programs and are pursuing various indications. Could you walk through how you and Lilly are setting indication priorities past the lupus? And since your existing projection covers the whole span, what standards will guide that subsequent choice? Thank you.

Howard Robin

executive
#82

Let's have JZ begin by taking the 358 topic, then we'll turn to the randomized control trial point Daina raised. Thanks.

Jonathan Zalevsky

executive
#83

All right. Hi Daina, good to talk with you. Now, regarding 358, as you're aware. Tregs have potential across many conditions. When we think about the various indications Lily and Nektar might pursue together, we examined several considerations. We examined, naturally, the strategic ones that align with the areas Lily is deeply involved in and putting first; and we also examined things quite scientifically, nearly from the ground up, asking where the fundamental disease pathology is most strongly propelled by a malfunctioning T-cell compartment, where that T-cell compartment's character is antigen driven, where we possess some grasp of at least a few of the main antigenic drivers. And then where we believe we can, naturally, produce antigen specific Tregs capable of countering autoreactive immune cells that react to that identical antigen. So we have methods for categorizing autoimmune diseases into those with varying inflammation types, based on which organ is affected, the local immunity within that organ; and that stretches from illnesses that are extremely inflammatory and cause, for instance conditions such as Crohn's, which are very, very strongly T cell driven inflammatory illnesses, likely with minimal autoimmune or humoral involvement. And then, it spans the spectrum right up to illnesses that are entirely autoimmune. Take, for instance, Pemphigus or Myasthenia, which are entirely propelled by an auto antibody. So you can picture that Tregs <<inaudible>> in those 2 distinct categories of illness addressed 2 distinct targets. In the first category, you'd essentially be countering T cells migrating to the gut, as you noted, or halting their inflammatory reaction to those antigens they respond to. Yet in the second scenario of that autoimmune illness, you'd anticipate countering T Follicular helper cells. Cells governing B cell, T cell responses and priming and bringing down any sort of auto antibody — sort of generation. So we can rank illnesses according to their fundamental immunology. Examine where 358 and the cell population it produces can have the greatest effect; and then employ that to choose an indication for evaluation; at present, with — Lilly <<inaudible>>, we don't reveal those indications in advance. So we'd reveal them once we draw significantly nearer to launching those trials. So keep watching as we reach later this year when we disclose the extra indications. So we'll be collaborating on together.

Howard Robin

executive
#84

Okay, well, thank you, and thanks to each of you for being here today. I especially want to express appreciation to the people who work at this company for the enormous effort and dedication they've shown, particularly while conditions around us are shifting so quickly. We've needed to change how we work and act differently. I feel incredibly proud of the way our team has stepped up to handle the obstacles we face each day, keep operations moving and achieve significant advances. So my thanks go out to all of them. In immuno-oncology and immunology, we've assembled a highly valuable pipeline that targets areas with substantial unmet medical need, and our attention is on advancing those programs. To those of you who hold shares, we appreciate your backing. We'll keep sharing news about how things are going. And we'd also like to wish each of you and your loved ones safety and good health right now. So thanks for being with us.

Operator

operator
#85

Thanks, everyone, for joining us on today's call. That brings the program to a close, so you're all free to hang up now. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.